176 related articles for article (PubMed ID: 24971463)
21. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
22. Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells.
Labsch S; Liu L; Bauer N; Zhang Y; Aleksandrowicz E; Gladkich J; Schönsiegel F; Herr I
Int J Oncol; 2014 May; 44(5):1470-80. PubMed ID: 24626333
[TBL] [Abstract][Full Text] [Related]
23. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Shankar S; Ganapathy S; Srivastava RK
Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
[TBL] [Abstract][Full Text] [Related]
24. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
25. [Thioridazine Sensitizes Apoptotic Effect of TRAIL in Human Lung Cancer PC9 Cells Through ER Stress Mediated Up-regulation of DR5].
Li J; Wang Y; Liu L; Yuan Y; Bao Y
Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):80-87. PubMed ID: 28228218
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.
Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS
PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339
[TBL] [Abstract][Full Text] [Related]
27. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
28. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
29. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
[TBL] [Abstract][Full Text] [Related]
30. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.
Tse AK; Chow KY; Cao HH; Cheng CY; Kwan HY; Yu H; Zhu GY; Wu YC; Fong WF; Yu ZL
J Biol Chem; 2013 Oct; 288(41):29923-33. PubMed ID: 23986445
[TBL] [Abstract][Full Text] [Related]
31. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
[TBL] [Abstract][Full Text] [Related]
32. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
33. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
34. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
[TBL] [Abstract][Full Text] [Related]
35. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
[TBL] [Abstract][Full Text] [Related]
36. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
37. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
38. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
39. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
